BRISBANE, Calif., March 20, 2015 (GLOBE NEWSWIRE) -- Cutera, Inc. (Nasdaq:CUTR), a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, announced today that the Korean Ministry of Food and Drug Safety granted regulatory clearance for its enlighten picosecond laser platform. Commercial shipments to Korea are planned to start this month.
"Korea has proven to be a key market for Cutera, and the earlier than anticipated clearance for our enlighten picosecond laser platform is an important international milestone. While we commenced modest initial international shipments this quarter, we expect a staged ramp up of revenue as we gain additional international regulatory clearances and build the necessary support structure. We believe this product will become a significant revenue contributor in the second half of 2015," said Kevin Connors, President and CEO of Cutera, Inc.
enlighten is the first and only high-powered, dual wavelength and dual pulse duration laser featuring picosecond technology. This product is 510(k) cleared by the U.S. Food and Drug Administration for tattoo removal and the treatment of benign pigmented lesions. The company commenced shipments in the U.S in December 2014.
About Cutera, Inc.
Brisbane, California-based Cutera is a leading provider of laser and other energy-based aesthetic systems for practitioners worldwide. Since 1998, Cutera has been developing innovative, easy-to-use products that enable physicians and other qualified practitioners to offer safe and effective aesthetic treatments to their patients. For more information, call 1-888-4CUTERA or visit www.cutera.com.
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Specifically, statements concerning the features, effectiveness, treatable conditions, timing of commercial sales and the impact of this product on our revenue, are forward-looking statements within the meaning of the Safe Harbor. Such forward-looking statements are subject to risks and uncertainties and may be affected by various factors that may cause actual results to differ materially from those in the forward-looking statements and those other factors described in the section entitled, "Risk Factors", in Cutera's most recent Form 10-K as filed with the Securities and Exchange Commission on March 16, 2015. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Cutera undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.
CONTACT: Cutera, Inc. Ron Santilli Chief Financial Officer 415-657-5500 Investor Relations John Mills Integrated Corporate Relations, Inc. 646-277-1254 email@example.com